To investigate the effects of butyphthalide soft capsule combined with atorvastatin calcium on neurological function recovery and activity of daily living of patients with cerebral infarction.

Sixty-eight patients with cerebral infarction were divided into control group(n=34) and study group (n=34) according to random number table method. The control group was treated by conventional measures, the study group, on the basis of treatment in control group, was treated with butyphthalide soft capsule and atorvastatin calcium, both groups were treated for 3 months. Neurological function score (NIHSS), activity of daily living score (ADL) and laboratory indexes [homocysteine (Hcy), angiotensin Ⅱ (ANG Ⅱ), neuron specificity enolase (NSE)] levels, clinical efficacy and the incidence of adverse reactions were statistically compared between the two groups at admission and after treatment.

The NIHSS and ADL score of study group were not significantly different from those of control group before treatment (P>0.05), but after treatment, the NIHSS and ADL score of study group were significantly lower than those of control group (P<0.05). The positive rate in study group [91.18% (31/34)] was significantly higher than that in control group [67.65%(23/34)], P<0.05. The levels of serum Hcy, ANGⅡ and NSE in study group were not significantly different from those in control group (P>0.05); but after treatment, the levels in study group were significantly lower than those in control group (P<0.05). There was no significant difference in the incidence of adverse events between study group [11.76% (4/34)] and control group [8.82% (3/34)], P>0.05.

Butyphthalide soft capsule combined with atorvastatin calcium gets significant effect in treatment of cerebral infarction, which can improve neurological function, activity of daily living of patients, and the therapeutic effect with high safety.

Butylphthalide soft capsules; Atorvastatin calcium tablets; Cerebral infarction; Neurological function; Daily living ability